Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope
Abstract The use of bacteria to specifically migrate to cancerous tissue and elicit an antitumor immune response provides a promising platform against cancer with significantly high potency. With dozens of clinical trials underway, some researchers hold the following views: “humans are nearing the f...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-01-01
|
Series: | Nano-Micro Letters |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40820-020-00560-9 |
id |
doaj-598f1b8e4729481fbf615270962dfdc5 |
---|---|
record_format |
Article |
spelling |
doaj-598f1b8e4729481fbf615270962dfdc52021-01-10T12:56:43ZengSpringerOpenNano-Micro Letters2311-67062150-55512021-01-0113112610.1007/s40820-020-00560-9Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big HopeXinyu Lou0Zhichao Chen1Zhonggui He2Mengchi Sun3Jin Sun4Wuya College of Innovation, Shenyang Pharmaceutical UniversityWuya College of Innovation, Shenyang Pharmaceutical UniversityWuya College of Innovation, Shenyang Pharmaceutical UniversityWuya College of Innovation, Shenyang Pharmaceutical UniversityWuya College of Innovation, Shenyang Pharmaceutical UniversityAbstract The use of bacteria to specifically migrate to cancerous tissue and elicit an antitumor immune response provides a promising platform against cancer with significantly high potency. With dozens of clinical trials underway, some researchers hold the following views: “humans are nearing the first commercial live bacteria therapeutic.” However, the facultative anaerobe Salmonella typhimurium VNP20009, which is particularly safe and shows anticancer effects in preclinical studies, had failed in a phase I clinical trial due to low tumor regression and undesired dose-dependent side effects. This is almost certain to disappoint people’s inflated expectations, but it is noted that recent state-of-the-art research has turned attention to bacteria-mediated synergistic cancer therapy (BMSCT). In this review, the foundation of bacteria-mediated bio-therapy is outlined. Then, we summarize the potential benefits and challenges of bacterial bio-therapy in combination with different traditional anticancer therapeutic modalities (chemotherapy, photothermal therapy, reactive oxygen and nitrogen species therapy, immunotherapy, or prodrug-activating therapy) in the past 5 years. Next, we discuss multiple administration routes of BMSCT, highlighting potentiated antitumor responses and avoidance of potential side effects. Finally, we envision the opportunities and challenges for BMSCT development, with the purpose of inspiring medicinal scientists to widely utilize the microbiome approach in patient populations.https://doi.org/10.1007/s40820-020-00560-9Bacteria-mediated synergistic cancer therapyMultiple administration routesAntitumor responsesPotential side effectsMicrobiome approach |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xinyu Lou Zhichao Chen Zhonggui He Mengchi Sun Jin Sun |
spellingShingle |
Xinyu Lou Zhichao Chen Zhonggui He Mengchi Sun Jin Sun Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope Nano-Micro Letters Bacteria-mediated synergistic cancer therapy Multiple administration routes Antitumor responses Potential side effects Microbiome approach |
author_facet |
Xinyu Lou Zhichao Chen Zhonggui He Mengchi Sun Jin Sun |
author_sort |
Xinyu Lou |
title |
Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope |
title_short |
Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope |
title_full |
Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope |
title_fullStr |
Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope |
title_full_unstemmed |
Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope |
title_sort |
bacteria-mediated synergistic cancer therapy: small microbiome has a big hope |
publisher |
SpringerOpen |
series |
Nano-Micro Letters |
issn |
2311-6706 2150-5551 |
publishDate |
2021-01-01 |
description |
Abstract The use of bacteria to specifically migrate to cancerous tissue and elicit an antitumor immune response provides a promising platform against cancer with significantly high potency. With dozens of clinical trials underway, some researchers hold the following views: “humans are nearing the first commercial live bacteria therapeutic.” However, the facultative anaerobe Salmonella typhimurium VNP20009, which is particularly safe and shows anticancer effects in preclinical studies, had failed in a phase I clinical trial due to low tumor regression and undesired dose-dependent side effects. This is almost certain to disappoint people’s inflated expectations, but it is noted that recent state-of-the-art research has turned attention to bacteria-mediated synergistic cancer therapy (BMSCT). In this review, the foundation of bacteria-mediated bio-therapy is outlined. Then, we summarize the potential benefits and challenges of bacterial bio-therapy in combination with different traditional anticancer therapeutic modalities (chemotherapy, photothermal therapy, reactive oxygen and nitrogen species therapy, immunotherapy, or prodrug-activating therapy) in the past 5 years. Next, we discuss multiple administration routes of BMSCT, highlighting potentiated antitumor responses and avoidance of potential side effects. Finally, we envision the opportunities and challenges for BMSCT development, with the purpose of inspiring medicinal scientists to widely utilize the microbiome approach in patient populations. |
topic |
Bacteria-mediated synergistic cancer therapy Multiple administration routes Antitumor responses Potential side effects Microbiome approach |
url |
https://doi.org/10.1007/s40820-020-00560-9 |
work_keys_str_mv |
AT xinyulou bacteriamediatedsynergisticcancertherapysmallmicrobiomehasabighope AT zhichaochen bacteriamediatedsynergisticcancertherapysmallmicrobiomehasabighope AT zhongguihe bacteriamediatedsynergisticcancertherapysmallmicrobiomehasabighope AT mengchisun bacteriamediatedsynergisticcancertherapysmallmicrobiomehasabighope AT jinsun bacteriamediatedsynergisticcancertherapysmallmicrobiomehasabighope |
_version_ |
1724341972217364480 |